Technical Analysis for CLDI - Calidi Biotherapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Very Strong | Down | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Calm After Storm | Range Contraction | -6.11% | |
| Inside Day | Range Contraction | -6.11% | |
| Wide Bands | Range Expansion | -6.11% | |
| Calm After Storm | Range Contraction | -10.42% | |
| Outside Day | Range Expansion | -10.42% | |
| Wide Bands | Range Expansion | -10.42% | |
| Up 3 Days in a Row | Strength | -10.42% | |
| Calm After Storm | Range Contraction | -8.51% |
| Alert | Time |
|---|---|
| 10 DMA Resistance | about 4 hours ago |
| 1.5x Volume Pace | about 6 hours ago |
| Down 5% | about 6 hours ago |
| Down 3% | about 6 hours ago |
| Fell Below Previous Day's Low | about 6 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/29/2024
Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer with a novel stem cell-based therapy delivering a payload to target and kill tumor cells. Calidi Biotherapeutics is advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California.
Keywords: Biotechnology Cancer Solid Tumors Tumor Cancer Immunotherapy Stem Cell Cell Therapy Virotherapy Cell Biology Glioma Oncolytic Virus Akseli Hemminki Metastatic Disease
Classification
Keywords: Biotechnology Cancer Solid Tumors Tumor Cancer Immunotherapy Stem Cell Cell Therapy Virotherapy Cell Biology Glioma Oncolytic Virus Akseli Hemminki Metastatic Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 26.3 |
| 52 Week Low | 0.73 |
| Average Volume | 1,530,634 |
| 200-Day Moving Average | 2.76 |
| 50-Day Moving Average | 1.36 |
| 20-Day Moving Average | 1.75 |
| 10-Day Moving Average | 2.22 |
| Average True Range | 0.38 |
| RSI (14) | 56.90 |
| ADX | 54.63 |
| +DI | 35.92 |
| -DI | 9.34 |
| Chandelier Exit (Long, 3 ATRs) | 2.74 |
| Chandelier Exit (Short, 3 ATRs) | 1.88 |
| Upper Bollinger Bands | 2.92 |
| Lower Bollinger Band | 0.58 |
| Percent B (%b) | 0.67 |
| BandWidth | 133.84 |
| MACD Line | 0.31 |
| MACD Signal Line | 0.27 |
| MACD Histogram | 0.0442 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.56 | ||||
| Resistance 3 (R3) | 2.56 | 2.42 | 2.49 | ||
| Resistance 2 (R2) | 2.42 | 2.32 | 2.42 | 2.46 | |
| Resistance 1 (R1) | 2.29 | 2.26 | 2.22 | 2.29 | 2.44 |
| Pivot Point | 2.15 | 2.15 | 2.12 | 2.15 | 2.15 |
| Support 1 (S1) | 2.02 | 2.05 | 1.95 | 2.02 | 1.86 |
| Support 2 (S2) | 1.88 | 1.99 | 1.88 | 1.84 | |
| Support 3 (S3) | 1.75 | 1.88 | 1.81 | ||
| Support 4 (S4) | 1.75 |
